{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:21:06Z","timestamp":1773922866599,"version":"3.50.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T00:00:00Z","timestamp":1754179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Urology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ajur.2025.01.004","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:56:18Z","timestamp":1754441778000},"page":"445-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of reclassification and novel tools in active surveillance"],"prefix":"10.1016","volume":"12","author":[{"given":"B\u00e1rbara Vieira","family":"Lima Aguiar Mel\u00e3o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Mendes","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim A.","family":"Touijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajur.2025.01.004_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ajur.2025.01.004_bib2","first-page":"175","article-title":"Quantifying the role of PSA screening in the US prostate cancer mortality decline","volume":"19","author":"Etzioni","year":"2008","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ajur.2025.01.004_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib4","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.1994.03510290050036","article-title":"Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer","volume":"271","author":"Epstein","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.ajur.2025.01.004_bib5","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(96)09380-4","article-title":"Population-based study of long-term survival in patients with clinically localised prostate cancer","volume":"349","author":"Lu-Yao","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ajur.2025.01.004_bib6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jama.2019.20675","article-title":"Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"323","author":"Hoffman","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ajur.2025.01.004_bib7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajur.2025.01.004_bib8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.juro.2015.08.087","article-title":"Outcomes of active surveillance for clinically localized prostate cancer in the prospective, multi-institutional canary PASS cohort","volume":"195","author":"Newcomb","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"Active surveillance of Grade Group 1 prostate cancer: long-term outcomes from a large prospective cohort","volume":"77","author":"Tosoian","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/JU.0000000000001937","article-title":"Factors associated with time to conversion from active surveillance to treatment for prostate cancer in a multi-institutional cohort","volume":"206","author":"Cooley","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2012.11.005","article-title":"Active surveillance for low-risk prostate cancer worldwide: the PRIAS study","volume":"63","author":"Bul","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.juro.2010.09.095","article-title":"Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer","volume":"185","author":"Adamy","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.juro.2014.09.094","article-title":"Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer","volume":"193","author":"Welty","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2010.08.027","article-title":"Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment","volume":"58","author":"Soloway","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib15","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.clgc.2013.04.024","article-title":"Yonsei criteria: a new protocol for active surveillance in the era of robotic and local ablative surgeries","volume":"11","author":"Lim","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ajur.2025.01.004_bib16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.euo.2024.07.003","article-title":"Has active surveillance for prostate cancer become safer? Lessons learned from a global clinical registry","volume":"8","author":"Bangma","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ajur.2025.01.004_bib17","article-title":"Diagnostic accuracy of contemporary selection criteria in prostate cancer patients eligible for active surveillance: a Bayesian network meta-analysis","volume":"11","author":"Fan","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajur.2025.01.004_bib18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.eururo.2014.10.010","article-title":"Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification","volume":"67","author":"Loeb","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib19","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/JU.0000000000001186","article-title":"Risk factors for biopsy reclassification over time in men on active surveillance for early stage prostate cancer","volume":"204","author":"Lonergan","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib20","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1590\/s1677-5538.ibju.2017.0320","article-title":"Clinical and pathologic factors predicting reclassification in active surveillance cohorts","volume":"44","author":"Sierra","year":"2018","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib21","first-page":"1056","article-title":"Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study","volume":"52","author":"Tohi","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ajur.2025.01.004_bib22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/JU.0000000000002854","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/iju.12326","article-title":"Pathological upgrading and upstaging of patients eligible for active surveillance according to currently used protocols","volume":"21","author":"Kim","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/iju.12952","article-title":"Validation of active surveillance criteria for pathologically insignificant prostate cancer in Asian men","volume":"23","author":"Yamada","year":"2016","journal-title":"Int J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib26","first-page":"e1","article-title":"Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients","volume":"39:729.","author":"Bloom","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ajur.2025.01.004_bib27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41391-023-00693-z","article-title":"MRI lesion size is more important than the number of positive biopsy cores in predicting adverse features and recurrence after radical prostatectomy: implications for active surveillance criteria in intermediate-risk patients","volume":"27","author":"Baboudjian","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ajur.2025.01.004_bib28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41391-018-0101-6","article-title":"Validation of the decipher test for predicting adverse pathology in candidates for prostate cancer active surveillance","volume":"22","author":"Kim","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ajur.2025.01.004_bib29","doi-asserted-by":"crossref","first-page":"236","DOI":"10.6004\/jnccn.2023.0014","article-title":"NCCN guidelines\u00ae insights: prostate cancer early detection, version 1.2023","volume":"21","author":"Moses","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.ajur.2025.01.004_bib30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.juro.2018.08.043","article-title":"PI-RADS version 2 category on 3 Tesla multiparametric prostate magnetic resonance imaging predicts oncologic outcomes in Gleason 3+4 prostate cancer on biopsy","volume":"201","author":"Faiena","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib32","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1007\/s00345-019-03053-6","article-title":"Decreased accuracy of the prostate cancer EAU risk group classification in the era of imaging-guided diagnostic pathway: proposal for a new classification based on MRI-targeted biopsies and early oncologic outcomes after surgery","volume":"38","author":"Ploussard","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib33","article-title":"Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"4","author":"Drost","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajur.2025.01.004_bib34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2019.10.007","article-title":"Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up","volume":"77","author":"Klotz","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib35","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE Study)","volume":"76","author":"Lam","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib36","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/bju.14358","article-title":"Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis","volume":"122","author":"Schoots","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.ajur.2025.01.004_bib37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/pcan.2016.16","article-title":"Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance","volume":"19","author":"Radtke","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ajur.2025.01.004_bib38","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00345-014-1314-5","article-title":"The role of MRI-targeted and confirmatory biopsies for cancer upstaging at selection in patients considered for active surveillance for clinically low-risk prostate cancer","volume":"32","author":"Marliere","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib39","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/bju.15272","article-title":"Multiparametric magnetic resonance imaging facilitates reclassification during active surveillance for prostate cancer","volume":"127","author":"Fujihara","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.ajur.2025.01.004_bib40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","article-title":"Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis","volume":"80","author":"Rajwa","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib41","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.eururo.2016.06.011","article-title":"Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations\u2014a report of a European School of Oncology Task Force","volume":"71","author":"Moore","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib42","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eururo.2024.03.014","article-title":"PRECISE version 2: updated recommendations for reporting prostate magnetic resonance imaging in patients on active surveillance for prostate cancer","volume":"86","author":"Englman","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.rcl.2023.06.009","article-title":"Active surveillance for prostate cancer: expanding the role of MR imaging and the use of PRECISE criteria","volume":"62","author":"Englman","year":"2024","journal-title":"Radiol Clin"},{"key":"10.1016\/j.ajur.2025.01.004_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/jmri.25983","article-title":"Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: preliminary findings","author":"Algohary","year":"2018","journal-title":"J Magn Reson Imag"},{"key":"10.1016\/j.ajur.2025.01.004_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1166047","article-title":"Delta radiomic patterns on serial bi-parametric MRI are associated with pathologic upgrading in prostate cancer patients on active surveillance: preliminary findings","volume":"13","author":"Midya","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajur.2025.01.004_bib46","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s00330-021-08151-x","article-title":"Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance","volume":"32","author":"Sushentsev","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ajur.2025.01.004_bib47","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1007\/s00330-023-09438-x","article-title":"Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance","volume":"33","author":"Sushentsev","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ajur.2025.01.004_bib48","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ajur.2025.01.004_bib49","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib50","first-page":"1644","article-title":"The PRIMARY score: using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ajur.2025.01.004_bib51","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00259-023-06556-y","article-title":"Prediction of clinically significant prostate cancer by [68Ga]Ga-PSMA-11 PET\/CT: a potential tool for selecting patients for active surveillance","volume":"51","author":"Akcay","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ajur.2025.01.004_bib52","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.euo.2023.05.004","article-title":"Gallium-68 prostate-specific membrane antigen positron emission tomography\/computed tomography in active surveillance for prostate cancer trial (PASPoRT)","volume":"7","author":"Heetman","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ajur.2025.01.004_bib53","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.3390\/jcm11123473","article-title":"Could 68Ga-PSMA PET\/CT evaluation reduce the number of scheduled prostate biopsies in men enrolled in active surveillance protocols?","volume":"11","author":"Pepe","year":"2022","journal-title":"J Clin Med"},{"issue":"Suppl. 4","key":"10.1016\/j.ajur.2025.01.004_bib54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bju.16214","article-title":"The CONFIRM trial protocol: the utility of prostate-specific membrane antigen positron emission tomography\/computed tomography in active surveillance for prostate cancer","volume":"133","author":"Bagguley","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.ajur.2025.01.004_bib55","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.21037\/tau-22-708","article-title":"Ga-PSMA-PET\/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study","volume":"12","author":"Gondoputro","year":"2023","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib56","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.juro.2012.06.009","article-title":"Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer","volume":"188","author":"Tosoian","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib57","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00432-013-1566-2","article-title":"The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort","volume":"140","author":"Hirama","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ajur.2025.01.004_bib58","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00345-015-1643-z","article-title":"PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance","volume":"34","author":"Cantiello","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib59","doi-asserted-by":"crossref","first-page":"163.e15","DOI":"10.1016\/j.urolonc.2014.12.002","article-title":"Prognostic accuracy of Prostate Health Index and urinary prostate cancer antigen 3 in predicting pathologic features after radical prostatectomy","volume":"33","author":"Cantiello","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ajur.2025.01.004_bib60","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41391-021-00422-4","article-title":"Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN","volume":"25","author":"Kato","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ajur.2025.01.004_bib61","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.eururo.2016.11.017","article-title":"Evaluating the four kallikrein panel of the 4Kscore for prediction of high-grade prostate cancer in men in the Canary Prostate Active Surveillance Study","volume":"72","author":"Lin","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41391-018-0074-5","article-title":"Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance","volume":"22","author":"Borque-Fernando","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ajur.2025.01.004_bib63","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv095","article-title":"Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study","volume":"107","author":"Bryant","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajur.2025.01.004_bib64","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.3390\/ijms22126266","article-title":"Active surveillance in prostate cancer: role of available biomarkers in daily practice","volume":"22","author":"Pastor-Navarro","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajur.2025.01.004_bib65","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/pcan.2017.16","article-title":"Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance","volume":"20","author":"Tosoian","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ajur.2025.01.004_bib66","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41391-018-0124-z","article-title":"Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS)","volume":"22","author":"Newcomb","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ajur.2025.01.004_bib67","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00345-021-03609-5","article-title":"Liquid biomarkers in active surveillance","volume":"40","author":"Dall'Era","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib68","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1186\/s12885-015-1612-3","article-title":"The transcription factor ERG increases expression of neurotransmitter receptors on prostate cancer cells","volume":"15","author":"Kissick","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajur.2025.01.004_bib69","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-12-3283","article-title":"Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study","volume":"19","author":"Lin","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajur.2025.01.004_bib70","article-title":"The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies","volume":"63","author":"Berg","year":"2016","journal-title":"Dan Med J"},{"key":"10.1016\/j.ajur.2025.01.004_bib71","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3389\/fonc.2018.00623","article-title":"Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis","volume":"8","author":"Hupe","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajur.2025.01.004_bib72","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.3390\/ijms242216022","article-title":"Prostate-specific membrane antigen (PSMA) expression predicts need for early treatment in prostate cancer patients managed with active surveillance","volume":"24","author":"Ahmadi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajur.2025.01.004_bib73","unstructured":"Cornford P, Tilki D, Van den Bergh RCN, Briers E, Eberli D, De Meerleer G, et al. EAU Prostate Cancer Guidelines. https:\/\/uroweb.org\/guidelines\/prostate-cancer. [Accessed December 2023]."},{"key":"10.1016\/j.ajur.2025.01.004_bib74","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.3390\/cancers13174251","article-title":"Biomarker in active surveillance for prostate cancer: a systematic review","volume":"13","author":"Manceau","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajur.2025.01.004_bib75","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.eururo.2014.05.004","article-title":"A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling","volume":"66","author":"Klein","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib76","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.urology.2018.11.050","article-title":"A 17-gene panel for prediction of adverse prostate cancer pathologic features: prospective clinical validation and utility","volume":"126","author":"Eggener","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.ajur.2025.01.004_bib77","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.juro.2018.08.047","article-title":"Genomic Prostate Score, PI-RADS\u2122 version 2 and progression in men with prostate cancer on active surveillance","volume":"201","author":"Kornberg","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib78","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/JU.0000000000000271","article-title":"Stability of a 17-gene Genomic Prostate Score in serial testing of men on active surveillance for early stage prostate cancer","volume":"202","author":"Cedars","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib79","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1200\/JCO.19.02267","article-title":"17-gene Genomic Prostate Score test results in the Canary Prostate Active Surveillance Study (PASS) cohort","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajur.2025.01.004_bib80","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.juro.2017.09.077","article-title":"Genomic scores are independent of disease volume in men with favorable risk prostate cancer: implications for choosing men for active surveillance","volume":"199","author":"Nyame","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib81","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1470-2045(10)70295-3","article-title":"Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajur.2025.01.004_bib82","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41391-019-0159-9","article-title":"Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy","volume":"23","author":"Canter","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ajur.2025.01.004_bib83","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2012.46.4396","article-title":"Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort","volume":"31","author":"Cooperberg","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajur.2025.01.004_bib84","first-page":"e7","article-title":"Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance","volume":"36:310","author":"Lin","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ajur.2025.01.004_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066855","article-title":"Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy","volume":"8","author":"Erho","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ajur.2025.01.004_bib86","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.urology.2016.01.012","article-title":"Decipher genomic classifier measured on prostate biopsy predicts metastasis risk","volume":"90","author":"Klein","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.ajur.2025.01.004_bib87","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.euros.2022.01.008","article-title":"Association between a 22-feature genomic classifier and biopsy Gleason upgrade during active surveillance for prostate cancer","volume":"37","author":"Press","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.ajur.2025.01.004_bib88","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00345-021-03610-y","article-title":"A review on the role of tissue-based molecular biomarkers for active surveillance","volume":"40","author":"Banerjee","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.ajur.2025.01.004_bib89","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1158\/1078-0432.CCR-14-2603","article-title":"Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer","volume":"21","author":"Blume-Jensen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajur.2025.01.004_bib90","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ccell.2021.04.002","article-title":"Artificial intelligence for clinical oncology","volume":"39","author":"Kann","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajur.2025.01.004_bib91","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41746-022-00613-w","article-title":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","volume":"5","author":"Esteva","year":"2022","journal-title":"NPJ Digit Med"}],"container-title":["Asian Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214388225000839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214388225000839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:09:15Z","timestamp":1773907755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214388225000839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":91,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2214388225000839"],"URL":"https:\/\/doi.org\/10.1016\/j.ajur.2025.01.004","relation":{},"ISSN":["2214-3882"],"issn-type":[{"value":"2214-3882","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of reclassification and novel tools in active surveillance","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajur.2025.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Editorial Office of Asian Journal of Urology. Publishing services by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}